Literature DB >> 34912096

What's next for PARP inhibitors?

Simon Makin.   

Abstract

Entities:  

Keywords:  Cancer; Health care; Therapeutics

Year:  2021        PMID: 34912096     DOI: 10.1038/d41586-021-03714-w

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  11 in total

1.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Antonio González-Martín; Bhavana Pothuri; Ignace Vergote; René DePont Christensen; Whitney Graybill; Mansoor R Mirza; Colleen McCormick; Domenica Lorusso; Paul Hoskins; Gilles Freyer; Klaus Baumann; Kris Jardon; Andrés Redondo; Richard G Moore; Christof Vulsteke; Roisin E O'Cearbhaill; Bente Lund; Floor Backes; Pilar Barretina-Ginesta; Ashley F Haggerty; Maria J Rubio-Pérez; Mark S Shahin; Giorgia Mangili; William H Bradley; Ilan Bruchim; Kaiming Sun; Izabela A Malinowska; Yong Li; Divya Gupta; Bradley J Monk
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

2.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Authors:  Eric Pujade-Lauraine; Jonathan A Ledermann; Frédéric Selle; Val Gebski; Richard T Penson; Amit M Oza; Jacob Korach; Tomasz Huzarski; Andrés Poveda; Sandro Pignata; Michael Friedlander; Nicoletta Colombo; Philipp Harter; Keiichi Fujiwara; Isabelle Ray-Coquard; Susana Banerjee; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Patricia Pautier
Journal:  Lancet Oncol       Date:  2017-07-25       Impact factor: 41.316

3.  ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

Authors:  R E Miller; A Leary; C L Scott; V Serra; C J Lord; D Bowtell; D K Chang; D W Garsed; J Jonkers; J A Ledermann; S Nik-Zainal; I Ray-Coquard; S P Shah; X Matias-Guiu; E M Swisher; L R Yates
Journal:  Ann Oncol       Date:  2020-09-28       Impact factor: 32.976

4.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

Authors:  Isabelle Ray-Coquard; Patricia Pautier; Sandro Pignata; David Pérol; Antonio González-Martín; Regina Berger; Keiichi Fujiwara; Ignace Vergote; Nicoletta Colombo; Johanna Mäenpää; Frédéric Selle; Jalid Sehouli; Domenica Lorusso; Eva M Guerra Alía; Alexander Reinthaller; Shoji Nagao; Claudia Lefeuvre-Plesse; Ulrich Canzler; Giovanni Scambia; Alain Lortholary; Frederik Marmé; Pierre Combe; Nikolaus de Gregorio; Manuel Rodrigues; Paul Buderath; Coraline Dubot; Alexander Burges; Benoît You; Eric Pujade-Lauraine; Philipp Harter
Journal:  N Engl J Med       Date:  2019-12-19       Impact factor: 91.245

5.  Structural basis for allosteric PARP-1 retention on DNA breaks.

Authors:  Levani Zandarashvili; Marie-France Langelier; Uday Kiran Velagapudi; Mark A Hancock; Jamin D Steffen; Ramya Billur; Zain M Hannan; Andrew J Wicks; Dragomir B Krastev; Stephen J Pettitt; Christopher J Lord; Tanaji T Talele; John M Pascal; Ben E Black
Journal:  Science       Date:  2020-04-03       Impact factor: 47.728

6.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

Authors:  Robert L Coleman; Gini F Fleming; Mark F Brady; Elizabeth M Swisher; Karina D Steffensen; Michael Friedlander; Aikou Okamoto; Kathleen N Moore; Noa Efrat Ben-Baruch; Theresa L Werner; Noelle G Cloven; Ana Oaknin; Paul A DiSilvestro; Mark A Morgan; Joo-Hyun Nam; Charles A Leath; Shibani Nicum; Andrea R Hagemann; Ramey D Littell; David Cella; Sally Baron-Hay; Jesus Garcia-Donas; Mika Mizuno; Katherine Bell-McGuinn; Danielle M Sullivan; Bruce A Bach; Sudipta Bhattacharya; Christine K Ratajczak; Peter J Ansell; Minh H Dinh; Carol Aghajanian; Michael A Bookman
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

7.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro
Journal:  N Engl J Med       Date:  2018-10-21       Impact factor: 91.245

Review 8.  The forefront of ovarian cancer therapy: update on PARP inhibitors.

Authors:  M R Mirza; R L Coleman; A González-Martín; K N Moore; N Colombo; I Ray-Coquard; S Pignata
Journal:  Ann Oncol       Date:  2020-06-20       Impact factor: 32.976

9.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

10.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.